Neurological Biomarker Market Global Trends, Size, Segments and Growth till 2027

1
Neurological Biomarker Market Trends, Size,
Segments, Emerging Technologies 2027

• Published Date May 2022

Email sales_at_theinsightpartners.com
2
Report Studies
Email sales_at_theinsightpartners.com

• Neurological Biomarker Market Forecast to 2027 -
  COVID-19 Impact and Global Analysis by Product
  (Proteomics Biomarker, Genomics Biomarker,
  Metabolomics Biomarker, Imaging Biomarker,
  Others) Application (Alzheimer's Disease,
  Parkinson's Disease, Schizophrenia, Huntington's
  Disease, Spinal Muscular Atrophy, Others) End
  User (Pharmaceutical and Biotechnology Companies,
  Clinical Diagnostics, Research Organizations)
  and Geography

3
Neurological Biomarker Market Overview
Email sales_at_theinsightpartners.com

• The Neurological Biomarker Market is expected to
  reach US 14,454.7 million by 2027 from US
  5,501.8 million in 2019. The market is estimated
  to grow at a CAGR of 13.0 from 2020 to 2027.
• The genomic biomarkers segment held the largest
  share of the global neurological biomarker
  market, based on product, in 2019, and it is
  expected to register the highest CAGR during the
  forecast period. This segment is likely to
  witness a lucrative growth owing to increasing
  consumer awarenessabout the benefits of genetic
  medicines as well as technological advancements
  in the field of neurological biomarkers. In
  addition, the growing inclination toward gene
  counseling and genetic analysis for diagnostic
  purposes is also likely to propel the growth of
  the market for genomic biomarkers. The genetic
  biomarkers are significant modalities that
  directs towards a more personalized approach of
  predispositions and medical analysis.

4
Key Segment Market
Email sales_at_theinsightpartners.com

• Segment By Type-
• By Product (Proteomics Biomarker, Genomics
  Biomarker, Metabolomics Biomarker, Imaging
  Biomarker, Others)
• Application (Alzheimer's Disease, Parkinson's
  Disease, Schizophrenia, Huntington's Disease,
  Spinal Muscular Atrophy, Others)
• End-User (Pharmaceutical and Biotechnology
  Companies, Clinical Diagnostics, Research
  Organizations)

Download Sample
5
Neurological Biomarker Market Value
Email sales_at_theinsightpartners.com

• CAGR of 13
• (2020 - 2027)

Download Sample
6
Company Profiles
Email sales_at_theinsightpartners.com

• Thermo Fisher Scientific Inc.
• Abbott
• Myriad Genetics Inc.
• Bio-Rad Laboratories Inc.
• Qiagen Banyan Biomarkers Inc.
• Immunarray Pvt. Ltd.
• Quest Diagnostics Incorporated
• PerkinElmer, Inc.
• Merck Millipore

Download Sample
7
By Geography
Email sales_at_theinsightpartners.com

• North America (the US, Canada, and Mexico)
• Europe (the UK, Germany, France, Italy, Spain,
  and the Rest of Europe)
• Asia Pacific (China, Japan, India, Australia,
  South Korea, and the Rest of Asia Pacific)
• Middle East Africa (the UAE, Saudi Arabia,
  South Africa, and the Rest of Middle East
  Africa)
• South Central America (Brazil, Argentina, and
  the Rest of South Central America).

8
THANKYOU!

• Phone  [phone]

• E-Mail sales_at_theinsightpartners.com